Neratinib after trastuzumab in patients with HER2-positive breast cancer.
Shionogi and Co Ltd, Osaka, Japan.
Takahiro
T
Hasegawa
Dana-Farber Cancer Institute, Boston MA, USA.
Hajime
H
Uno
Harvard University, Boston MA, USA. Electronic address: wei@hsph.harvard.edu.
Lee-Jen
LJ
Wei
D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D005260:Female; D006801:Humans; D011804:Quinolines / Q000627:therapeutic use*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics; D000068878:Trastuzumab / Q000627:therapeutic use*
D011804:Quinolines; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human; C487932:neratinib